Yangfeng Du

机构：Central South University, The First People's Hospital of Changde, First Affiliated Hospital of Jinan University

发表论文 20 篇 · 总被引 116 次 · h-index 6

代表论文

• Efficacy and Safety in Proton Therapy and Photon Therapy for Patients With Esophageal Cancer (2023 · JAMA Network Open · 被引 34)
• Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial (2025 · Signal Transduction and Targeted Therapy · 被引 20)
• THSWD upregulates the LTF/AMPK/mTOR/Becn1 axis and promotes lysosomal autophagy in hepatocellular carcinoma cells by regulating gut flora and metabolic reprogramming (2025 · International Immunopharmacology · 被引 14)
• Cadonilimab (PD-1/CTLA-4) in combination with lenvatinib in unresectable hepatocellular carcinoma (uHCC): A retrospective real-world study (2024 · Heliyon · 被引 9)
• QKI-induced circ_0001766 inhibits colorectal cancer progression and rapamycin resistance by miR-1203/PPP1R3C/mTOR/Myc axis (2025 · Cell Death Discovery · 被引 8)
• Successful treatment with tislelizumab plus chemotherapy for SMARCA4-deficient undifferentiated tumor: a case report (2024 · Frontiers in Immunology · 被引 7)